GB201520570D0 - Peptides - Google Patents

Peptides

Info

Publication number
GB201520570D0
GB201520570D0 GBGB1520570.1A GB201520570A GB201520570D0 GB 201520570 D0 GB201520570 D0 GB 201520570D0 GB 201520570 A GB201520570 A GB 201520570A GB 201520570 D0 GB201520570 D0 GB 201520570D0
Authority
GB
United Kingdom
Prior art keywords
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1520570.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd & Adaptimmune Ltd
Original Assignee
Immunocore Ltd & Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd & Adaptimmune Ltd filed Critical Immunocore Ltd & Adaptimmune Ltd
Priority to GBGB1520570.1A priority Critical patent/GB201520570D0/en
Publication of GB201520570D0 publication Critical patent/GB201520570D0/en
Priority to EP16805200.9A priority patent/EP3380490B1/en
Priority to US15/777,613 priority patent/US20180339028A1/en
Priority to PCT/GB2016/053665 priority patent/WO2017089783A1/en
Priority to US17/104,415 priority patent/US20210138054A1/en
Priority to US18/064,180 priority patent/US20230346885A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
GBGB1520570.1A 2015-11-23 2015-11-23 Peptides Ceased GB201520570D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1520570.1A GB201520570D0 (en) 2015-11-23 2015-11-23 Peptides
EP16805200.9A EP3380490B1 (en) 2015-11-23 2016-11-23 Peptides
US15/777,613 US20180339028A1 (en) 2015-11-23 2016-11-23 Peptides
PCT/GB2016/053665 WO2017089783A1 (en) 2015-11-23 2016-11-23 Peptides
US17/104,415 US20210138054A1 (en) 2015-11-23 2020-11-25 Peptides derived from prostate specific antigen (klk3) and complexes comprising such peptides bound to mhc molecules
US18/064,180 US20230346885A1 (en) 2015-11-23 2022-12-09 Peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1520570.1A GB201520570D0 (en) 2015-11-23 2015-11-23 Peptides

Publications (1)

Publication Number Publication Date
GB201520570D0 true GB201520570D0 (en) 2016-01-06

Family

ID=55133170

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1520570.1A Ceased GB201520570D0 (en) 2015-11-23 2015-11-23 Peptides

Country Status (4)

Country Link
US (2) US20180339028A1 (en)
EP (1) EP3380490B1 (en)
GB (1) GB201520570D0 (en)
WO (1) WO2017089783A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
ATE533784T1 (en) 1997-10-02 2011-12-15 Altor Bioscience Corp SOLUBLE, SINGLE-CHAIN T-CELL RECEPTOR PROTEINS
US6759508B2 (en) * 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DK2336167T3 (en) 2001-03-14 2019-09-02 Dako Denmark As MHC molecular constructs and their use in diagnosis and therapy
ATE290020T1 (en) * 2001-08-31 2005-03-15 Avidex Ltd SOLUBLE T CELL RECEPTOR
DE10244457A1 (en) * 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Process for the rational mutagenesis of alpha / beta T-cell receptors and corresponding mutated MDM2 protein-specific alpha / beta T-cell receptors
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
CA2656583A1 (en) 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
EP2207564B1 (en) * 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
ME02810B (en) * 2010-09-20 2018-01-20 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
AU2014352826B2 (en) * 2013-11-22 2019-08-01 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human T cell receptors
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
EP3116901B1 (en) 2014-03-14 2019-06-12 Immunocore Limited Tcr libraries
JP6862343B2 (en) * 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． Cysteine-bonded nanobody dimer
RU2571551C1 (en) * 2015-04-16 2015-12-20 Закрытое акционерное общество "ПЕПТЕК" Specific combined therapy of malignant tumours with cytostatic agent and its modifying agent
ES2916092T3 (en) * 2016-12-08 2022-06-28 Immatics Biotechnologies Gmbh New receptors of T lymphocytes and immunotherapies based on their use

Also Published As

Publication number Publication date
US20210138054A1 (en) 2021-05-13
EP3380490A1 (en) 2018-10-03
EP3380490B1 (en) 2023-11-01
US20180339028A1 (en) 2018-11-29
WO2017089783A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
GB201520559D0 (en) Peptides
GB201520583D0 (en) Peptides
GB201520575D0 (en) Peptides
GB201520536D0 (en) Peptides
GB201520545D0 (en) Peptides
GB201520546D0 (en) Peptides
GB201520579D0 (en) Peptides
GB201520539D0 (en) Peptides
GB201520563D0 (en) Peptides
GB201520562D0 (en) Peptides
GB201520567D0 (en) Peptides
GB201520550D0 (en) Peptides
GB201520543D0 (en) Peptides
GB201520544D0 (en) Peptides
GB201520541D0 (en) Peptides
GB201520568D0 (en) Peptides
GB201520557D0 (en) Peptides
GB201520558D0 (en) Peptides
GB201520548D0 (en) Peptides
GB201520570D0 (en) Peptides
GB201520542D0 (en) Peptides
GB201520566D0 (en) Peptides
GB201520564D0 (en) Peptides
GB201520556D0 (en) Peptides
GB201520577D0 (en) Peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)